1. Home
  2. KRUS vs IRWD Comparison

KRUS vs IRWD Comparison

Compare KRUS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

N/A

Current Price

$34.96

Market Cap

485.4M

ML Signal

N/A

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

N/A

Current Price

$3.50

Market Cap

578.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRUS
IRWD
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.4M
578.3M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
KRUS
IRWD
Price
$34.96
$3.50
Analyst Decision
Buy
Buy
Analyst Count
9
4
Target Price
★ $62.88
$6.10
AVG Volume (30 Days)
193.0K
★ 1.7M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
★ 1400.00
EPS
N/A
★ 0.55
Revenue
$282,763,000.00
★ $298,276,000.00
Revenue This Year
$16.80
$59.19
Revenue Next Year
$17.77
$4.80
P/E Ratio
★ N/A
$6.54
Revenue Growth
★ 18.88
8.88
52 Week Low
$29.69
$1.76
52 Week High
$80.84
$5.78

Technical Indicators

Market Signals
Indicator
KRUS
IRWD
Relative Strength Index (RSI) 42.00 39.96
Support Level $33.97 $3.38
Resistance Level $41.99 $3.96
Average True Range (ATR) 1.77 0.16
MACD -0.13 0.01
Stochastic Oscillator 47.71 21.43

Price Performance

Historical Comparison
KRUS
IRWD

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: